Search - tctmd.com

Displaying 1 - 20 of 325

Sort: Relevancy | Date

Presentation TCT 2016

Learnings From A Pivotal Transcatheter Mitral Device Trial: Can The MVARC/COAPT Paradigm Be Shortened?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Presenter: Gregg W. Stone, Ron Waksman, John A. Ambrose

November 01, 2016

Presentation TCT 2016

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Presenter: Gregg W. Stone, Ron Waksman, Jonathan Leor

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Presenter: Gregg W. Stone, Ron Waksman, Seung-Jung Park

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Presenter: Gregg W. Stone, Ron Waksman, Vasim Farooq

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Case Introduction: How Would You Revascularize This Patient?

Presenter: John D. Puskas, Gregg W. Stone, Michael E. Halkos

November 01, 2016

Presentation TCT 2016

Announcing the NIH-sponsored HYBRID Revascularization Trial

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Hybrid Coronary Revascularization: Results to Date (From Meta-analysis to the NIH Multicenter Observational Study)

Presenter: John D. Puskas, Gregg W. Stone

November 01, 2016

Presentation TCT 2016

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

Presenter: John D. Puskas, Gregg W. Stone, John S. Douglas Jr

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Gregg W. Stone, Philippe Pibarot, Susheel K. Kodali

November 01, 2016

Presentation TCT 2016

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Presenter: Jonathan M. Hill, Dimitri Karmpaliotis, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

Presenter: Cindy L. Grines, Holger Thiele, Gregg W. Stone

October 31, 2016

Advertisement

Learnings From A Pivotal Transcatheter Mitral Device Trial: Can The MVARC/COAPT Paradigm Be Shortened?

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

FDA Perspectives on Short DAPT IDE Trials

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Put Away Your Catheters! Nanomedicines to Treat Vulnerable Plaque

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

To Treat or Not to Treat (Focally): From Stable to PROSPECT-ABSORB and PREVENT

Bioresorbable Scaffolds for Vulnerable Plaque Treatment: Rationale for Focal Therapy, Early Clinical Experiences, and Will it Succeed?!

Case Conclusion: How Did We Revascularize This Patient?

Case Introduction: How Would You Revascularize This Patient?

Announcing the NIH-sponsored HYBRID Revascularization Trial

Hybrid Coronary Revascularization: Results to Date (From Meta-analysis to the NIH Multicenter Observational Study)

Hybrid Coronary Revascularization: Rationale, Procedure Alternatives, and Technical Considerations

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient

Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content